Sunday, October 26, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Raises Price Target for Meta Platforms Signaling Optimism for Growth

Elaine Mendonca by Elaine Mendonca
February 2, 2024
in Breaking News
0
Technology Data analytics Stock Exchange
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

As of February 2, 2024, Doug Anmuth, an analyst at JP Morgan, continues to hold an optimistic view on Meta Platforms (NASDAQ:META) and has increased the price target from $420 to $535. This upward revision in the price target signifies a positive outlook for the company’s stock and indicates the possibility of significant growth. It is worth noting that other analysts also have their own price targets for Meta Platforms, resulting in a diverse range of forecasts. The average price target stands at $426.11, with the highest forecast at $470.00 and the lowest at $370.00. When making investment decisions, it is crucial to take into account the consensus and range of price targets provided by multiple analysts.

METAs Impressive Stock Market Performance on February 2, 2024: Strong Financial Results and Technological Advancements Drive 20.29% Increase

META, a leading technology company, had an impressive performance in the stock market on February 2, 2024. The stock opened at $459.83, $65.06 higher than its previous close, and continued to climb throughout the day, resulting in a 20.29% increase. This surge in value is attributed to META’s strong financial results, technological advancements, and solid financial position. Investors have faith in META’s ability to continue delivering value, but it is important to consider other factors before making investment decisions.

META Stock Performance: Revenue, Net Income, and EPS Analysis – February 2, 2024

META stock performances on February 2, 2024 were influenced by the company’s financial performance over the past year. According to data from CNN Money, META reported a total revenue of $116.61 billion in the last year, which remained flat compared to the previous year. However, the company experienced a 6.71% increase in total revenue since the last quarter, with a reported revenue of $34.15 billion.

In terms of net income, META reported a net income of $23.20 billion in the last year, indicating a 41.07% decrease compared to the previous year. However, the company saw a significant improvement in net income since the last quarter, with a 48.73% increase and a reported net income of $11.58 billion.

Earnings per share (EPS) is an important metric for investors, as it indicates the profitability of a company on a per-share basis. META reported an EPS of $8.59 in the last year, reflecting a 37.65% decrease compared to the previous year. However, the company experienced a strong rebound in EPS since the last quarter, with a 47.1% increase and a reported EPS of $4.39.

These financial indicators provide valuable insights into META’s performance over the past year and the most recent quarter. While the company’s total revenue remained flat since last year, the 6.71% increase in revenue since the last quarter indicates a positive trend. Similarly, the significant improvements in net income and EPS since the last quarter suggest that META has been able to enhance its profitability and generate higher earnings per share.

Investors and analysts may interpret these financial figures differently. Some may view the decrease in net income and EPS compared to the previous year as a cause for concern, while others may focus on the positive rebound in these metrics since the last quarter. It is important to consider the overall market conditions and industry trends when analyzing a company’s financial performance.

As with any investment, it is crucial for investors to conduct thorough research and analysis before making any decisions. The information provided here offers a snapshot of META’s financial performance on February 2, 2024, but it is essential to consider additional factors and consult multiple sources to gain a comprehensive understanding of the company’s stock performances.

Tags: META
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Food Retailers Market Capitalization

Increasing Short Interest in Kraft Heinz Suggests Growing Bearish Sentiment

Healthcare Services Stock Exchange

Analyst Ratings and Price Targets for Quest Diagnostics

Alternative Energy Markets and money (1)

CN Energy Group Inc Secures Continued Listing on Nasdaq

Recommended

Unique Flight Experiences Offered for Rare Total Solar Eclipse Viewing

2 years ago
VanEck Gold Miners ETF Stock

Gold Mining ETF Reaches New Heights Amid Record Bullion Prices

3 weeks ago
Varonis Stock

Varonis Stock Positioned for Growth Amid AI and Cloud Expansion

4 weeks ago
Universal Technical Institute Stock

Universal Technical Institute Shares Decline Despite Strong Analyst Backing

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Nike NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Veru’s Survival Battle: Clinical Promise Versus Financial Reality

Biotech Firm’s Clinical Breakthrough Fuels Acquisition Speculation

Fuel Cell Giant Powers AI Boom: Can Bloom Energy Sustain Its Meteoric Rise?

Ollie’s Bargain Outlet Shares Face Pressure Despite Bullish Outlook

MP Materials Shares Face Sharp Decline Amid Valuation Concerns

Biotech Analyst Battle: Arcus Biosciences Faces Conflicting Outlooks

Trending

United Parcel Service Stock
Analysis

UPS Shares Approach Critical Juncture Ahead of Earnings

by Felix Baarz
October 26, 2025
0

United Parcel Service (UPS) faces a pivotal moment as it prepares to release third-quarter results on October...

Ecolab Stock

All Eyes on Ecolab as Q3 2025 Earnings Report Approaches

October 26, 2025
Dr. Reddy’s LaboratoriesADR Stock

Dr. Reddy’s Laboratories: Revenue Strength Confronts Profitability Concerns

October 26, 2025
Veru Stock

Veru’s Survival Battle: Clinical Promise Versus Financial Reality

October 26, 2025
Protagonist Therapeutics Stock

Biotech Firm’s Clinical Breakthrough Fuels Acquisition Speculation

October 26, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • UPS Shares Approach Critical Juncture Ahead of Earnings
  • All Eyes on Ecolab as Q3 2025 Earnings Report Approaches
  • Dr. Reddy’s Laboratories: Revenue Strength Confronts Profitability Concerns

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com